Literature DB >> 2791805

Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program.

B A Lashner1, M D Silverstein, S B Hanauer.   

Abstract

The risk of colon cancer in patients with ulcerative colitis is related to the duration and extent of disease. Prior reports have suggested that patients with onset of disease in childhood have a high risk of cancer. These risk factors were analyzed in 99 patients in a surveillance program of annual colonoscopy to detect mucosal dysplasia. All patients had pancolitis for at least eight years. The mean age at symptom onset was 23.2 years and the mean duration of disease at entry was 17 years. An average of 4.2 tests/patient were performed, and 91% were completely followed through 1985. Cancer risk was expressed as the hazard rate or the annual probability that a patient free of cancer would develop cancer after survival to a given time period. The hazard rate for high-grade dysplasia or cancer in patients with pancolitis measured from symptom onset was 2.5% at 20 years, 4% at 25 years, 7% at 30 years, 13% at 35 years, and 20% at 40 years. Sex was not a significant predictor of cancer, but older age at symptom onset was a predictor of dysplasia and cancer. From these data, the annual hazard rate of developing high-grade dysplasia or cancer can be estimated in patients with pancolitis based on an individual's age at symptom onset and duration of disease.

Entities:  

Mesh:

Year:  1989        PMID: 2791805     DOI: 10.1007/bf01537106

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  "Precancer" lesions in ulcerative colits. A retrospective study of rectal biopsy and colectomy specimens.

Authors:  J H Yardley; D F Keren
Journal:  Cancer       Date:  1974-09       Impact factor: 6.860

2.  Cancer risk in ulcerative colitis: scientific requirements for the study of prognosis.

Authors:  D L Sackett; G Whelan
Journal:  Gastroenterology       Date:  1980-06       Impact factor: 22.682

3.  Cancer in colitis: assessment of the individual risk by clinical and histological criteria.

Authors:  J E Lennard-Jones; B C Morson; J K Ritchie; D C Shove; C B Williams
Journal:  Gastroenterology       Date:  1977-12       Impact factor: 22.682

4.  Carcinoma and epithelial dysplasia complicating ulcerative colitis.

Authors:  M G Cook; J C Goligher
Journal:  Gastroenterology       Date:  1975-05       Impact factor: 22.682

Review 5.  Dysplasia and malignancy in inflammatory bowel disease.

Authors:  W O Dobbins
Journal:  Annu Rev Med       Date:  1984       Impact factor: 13.739

6.  Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy.

Authors:  M O Blackstone; R H Riddell; B H Rogers; B Levin
Journal:  Gastroenterology       Date:  1981-02       Impact factor: 22.682

7.  Mucosal dysplasia. A major predictor of cancer following ileorectal anastomosis.

Authors:  W R Johnson; F T McDermott; E Pihl; E S Hughes
Journal:  Dis Colon Rectum       Date:  1983-11       Impact factor: 4.585

8.  Prevalence and incidence of inflammatory bowel disease in family members.

Authors:  B A Lashner; A A Evans; J B Kirsner; S B Hanauer
Journal:  Gastroenterology       Date:  1986-12       Impact factor: 22.682

9.  Mortality in ulcerative colitis.

Authors:  S Gyde; P Prior; M J Dew; V Saunders; J A Waterhouse; R N Allan
Journal:  Gastroenterology       Date:  1982-07       Impact factor: 22.682

10.  Optimal timing of colonoscopy to screen for cancer in ulcerative colitis.

Authors:  B A Lashner; S B Hanauer; M D Silverstein
Journal:  Ann Intern Med       Date:  1988-02       Impact factor: 25.391

View more
  26 in total

1.  Ten year follow up of ulcerative colitis patients with and without low grade dysplasia.

Authors:  C H Lim; M F Dixon; A Vail; D Forman; D A F Lynch; A T R Axon
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

Review 2.  The approach to dysplasia surveillance in inflammatory bowel disease.

Authors:  Remo Panaccione
Journal:  Can J Gastroenterol       Date:  2006-04       Impact factor: 3.522

3.  Increased circulating concentrations of growth-related oncogene (GRO)-alpha in patients with inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Osamu Tsuruta; Nobuo Tomiyasu; Kosuke Takaki; Asuka Suzuki; Junya Masuda; Hiroshi Yamasaki; Atsushi Toyonaga; Michio Sata
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

4.  Management of dysplasia in ulcerative colitis: is prophylactic colectomy the preferred strategy?

Authors:  T Axon
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

5.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 6.  Cancer surveillance in ulcerative colitis--a time for reappraisal.

Authors:  A T Axon
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

7.  Colorectal cancer and Crohn's colitis: clinical implications from 313 surgical patients.

Authors:  Stefano Scaringi; Carmela Di Martino; Daniela Zambonin; Marilena Fazi; Giuseppe Canonico; Francesca Leo; Ferdinando Ficari; Francesco Tonelli
Journal:  World J Surg       Date:  2013-04       Impact factor: 3.352

Review 8.  Failure of colonoscopic surveillance in ulcerative colitis.

Authors:  D A Lynch; A J Lobo; G M Sobala; M F Dixon; A T Axon
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

9.  Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis.

Authors:  B A Lashner
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

10.  Dysplasia and carcinoma in longstanding ulcerative colitis: an endoscopic and histological surveillance programme.

Authors:  M Leidenius; I Kellokumpu; A Husa; M Riihelä; P Sipponen
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.